186
Participants
Start Date
July 8, 2014
Primary Completion Date
January 18, 2024
Study Completion Date
January 18, 2024
Guided Therapy
A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
The Children's Hospital at Montefiore, The Bronx
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Levine Children's Hospital, Charlotte
Medical University of South Carolina, Charleston
Arnold Palmer Hospital for Children, Orlando
Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville
Helen DeVos Children's Hospital, Grand Rapids
Children's Hospital and Clinics on Minnesota, Minneapolis
Cardinal Glennon Children's Medical Center, St Louis
Children's Mercy Hospitals and Clinics, Kansas City
Arkansas Children's Hospital, Little Rock
Texas Children's Cancer and Hematology Centers, Houston
Dell Children's Blood and Cancer Center, Austin
Primary Children's Hospital, Salt Lake City
Rady Children's Hospital, San Diego
Kapiolani Medical Center for Women and Children, Honolulu
Connecticut Children's Hospital, Hartford
Randall Children's Hospital, Portland
American University of Beirut Medical Center, Beirut
Translational Genomics Research Institute
OTHER
Dell, Inc.
INDUSTRY
Giselle Sholler
OTHER